Biomarin Pharmaceutical Inc (BMRN)
Profitability ratios
Return on sales
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 78.98% | 78.30% | 77.60% | 77.20% | 76.77% | 76.52% | 76.19% | 75.66% | 75.03% | 74.25% | 73.93% | 70.28% | 70.64% | 71.24% | 72.89% | 77.82% | 78.47% | 78.78% | 78.81% | 78.90% |
| Operating profit margin | 7.66% | 6.79% | 5.41% | 4.32% | 3.52% | 7.26% | 5.41% | 3.01% | 1.60% | -4.51% | -3.72% | -3.74% | -6.79% | -2.38% | -0.06% | 3.25% | 3.30% | -5.93% | -8.10% | -9.82% |
| Pretax margin | 9.72% | 7.95% | 6.71% | 4.95% | 3.40% | 7.26% | 5.03% | 2.96% | 1.90% | -4.12% | -3.04% | -3.74% | -7.00% | -2.69% | -0.65% | 3.26% | 3.36% | -5.60% | -8.03% | -10.37% |
| Net profit margin | 8.41% | 7.06% | 6.50% | 4.58% | 3.37% | 6.87% | 4.20% | 2.84% | 2.10% | -3.51% | 0.59% | 43.99% | 43.52% | 46.85% | 46.75% | 6.74% | 6.43% | -1.41% | -2.66% | -7.25% |
Biomarin Pharmaceutical Inc has shown a generally improving trend in profitability ratios over the past few quarters. The gross profit margin has been consistently high, ranging from 76.77% to 78.98% in the most recent quarter. This indicates the company has been effective in managing its cost of goods sold.
In terms of operating profit margin, Biomarin has shown improvement, with a positive trend. Despite some fluctuations, the operating profit margin has increased from 3.52% to 7.66% in the most recent quarter, indicating efficient cost management and operational performance.
Similarly, the pretax margin has also shown improvement, reflecting the company's ability to generate profit before taxes. The pretax margin increased from 3.40% to 9.72% in the most recent quarter, indicating improved profitability and operational efficiency.
The net profit margin, representing the company's bottom line profitability, has also shown improvement over the quarters. Despite some fluctuations, the net profit margin increased from 3.37% to 8.41% in the most recent quarter, indicating that Biomarin has been able to translate its revenues into higher profits.
Overall, Biomarin Pharmaceutical Inc's profitability ratios demonstrate improving operational efficiency and cost management, leading to higher margins and profitability over the analyzed period.
Return on investment
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 2.72% | 2.36% | 1.81% | 1.44% | 1.16% | 2.35% | 1.73% | 0.93% | 0.49% | -1.37% | -1.14% | -1.20% | -2.12% | -0.74% | -0.02% | 1.11% | 1.24% | -2.14% | -2.84% | -3.40% |
| Return on assets (ROA) | 2.99% | 2.45% | 2.18% | 1.52% | 1.11% | 2.22% | 1.34% | 0.88% | 0.65% | -1.07% | 0.18% | 14.11% | 13.61% | 14.60% | 13.84% | 2.31% | 2.41% | -0.51% | -0.93% | -2.51% |
| Return on total capital | 4.49% | 3.71% | 3.03% | 2.11% | 1.53% | 2.91% | 2.07% | 1.28% | 0.93% | -1.12% | -0.74% | -0.92% | -1.93% | -0.38% | 0.38% | 1.95% | 2.23% | -1.98% | -2.66% | -3.27% |
| Return on equity (ROE) | 4.05% | 3.39% | 3.00% | 2.09% | 1.54% | 3.08% | 1.84% | 1.20% | 0.90% | -1.50% | 0.25% | 19.64% | 18.98% | 20.83% | 21.02% | 3.78% | 3.52% | -0.76% | -1.38% | -3.72% |
Biomarin Pharmaceutical Inc's profitability ratios have shown fluctuating trends over the past several quarters.
1. Operating return on assets (Operating ROA) has ranged from -3.40% to 2.72% with a recent increase to 2.72%, indicating the company's ability to generate operating profits from its assets.
2. Return on assets (ROA) has also varied significantly, with values ranging from -2.51% to 14.60%. The recent ROA of 2.99% demonstrates the company's overall ability to generate profits from its total assets.
3. Return on total capital has fluctuated between -3.27% and 4.49%. The recent value of 4.49% suggests that the company is generating profits relative to its total capital investment.
4. Return on equity (ROE) has shown a wide range of values from -3.72% to 21.02%. The most recent ROE of 4.05% indicates the company's profitability in generating returns for its shareholders.
Overall, Biomarin Pharmaceutical Inc's profitability ratios have displayed mixed performance, with recent improvements in some measures suggesting increased profitability and efficiency in utilizing assets and capital.